Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tyra Biosciences is a clinical-stage precision oncology company developing FGFR-targeted therapies for genetically defined cancers. The company's lead asset, TYRA-300, is a selective FGFR3 inhibitor in Phase 2 trials for bladder cancer and other solid tumors with FGFR3 alterations, while TYRA-200 targets FGFR1/2/3 for broader indications. With no revenue, $170M+ cash runway (estimated based on 17.71 current ratio), and recent 171% six-month stock surge, the company trades purely on clinical trial readouts and partnership potential.
Tyra operates a classic biotech model: raise capital through equity offerings, invest in R&D to advance drug candidates through FDA trials (Phase 1/2/3), then monetize via either direct commercialization post-approval or out-licensing to larger pharma partners. Competitive advantage lies in proprietary SNÅP platform for designing kinase inhibitors with improved selectivity profiles versus existing FGFR inhibitors (erdafitinib, pemigatinib), potentially reducing dose-limiting toxicities like hyperphosphatemia. Value inflection points occur at clinical data readouts demonstrating efficacy/safety superiority. The FGFR inhibitor market addresses ~$500M+ opportunity in bladder cancer alone, with potential expansion into cholangiocarcinoma and other FGFR-driven malignancies.
TYRA-300 Phase 2 clinical trial data releases - objective response rates (ORR), progression-free survival (PFS), and safety profile versus existing FGFR3 inhibitors in bladder cancer patients
FDA regulatory milestones - IND clearances for new indications, breakthrough therapy designation potential, or accelerated approval pathway eligibility
Partnership/licensing announcements with major pharma for co-development or commercialization rights (typical deals: $50-200M upfront + milestones)
Competitive landscape shifts - rival FGFR inhibitor trial failures/successes (Janssen's erdafitinib, Incyte's pemigatinib, Blueprint's fisogatinib)
Capital raises and cash runway updates - dilution concerns versus funding adequacy for trial completion
Binary clinical trial risk - Phase 2/3 failure rates exceed 60% in oncology; single negative readout could eliminate 50-80% of market value overnight
Competitive obsolescence risk - Next-generation FGFR inhibitors or alternative mechanisms (antibody-drug conjugates, cell therapies) could render small molecule approach less attractive before commercialization
Regulatory pathway uncertainty - FDA approval standards for FGFR inhibitors evolving; accelerated approval may require confirmatory trials with years of additional investment
Erdafitinib (Janssen) already approved for FGFR3+ bladder cancer with established market presence; TYRA-300 must demonstrate meaningful differentiation in head-to-head or cross-trial comparisons
Well-funded competitors (Blueprint Medicines $800M+ cash, Relay Therapeutics) advancing parallel FGFR programs with potentially faster timelines or broader indications
Combination therapy strategies from larger pharma (pairing FGFR inhibitors with checkpoint inhibitors) could establish treatment paradigms before TYRA reaches market
Dilution risk from future capital raises - clinical-stage companies typically require 2-3 additional financings before profitability; at current $1.6B market cap, 20-30% dilution likely over next 24 months
Cash runway pressure if trials extend beyond projections - enrollment delays or additional safety studies could accelerate burn rate and force financing at unfavorable terms
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D spending continues regardless of economic conditions, and cancer treatment demand is non-discretionary. However, financing environment sensitivity is high: risk-off markets reduce IPO/follow-on offering viability and compress biotech valuations. The 131% one-year return reflects 2025's biotech rally amid improved risk appetite.
High sensitivity through valuation mechanism rather than operations. Pre-revenue biotechs are discounted cash flow stories with payoffs 5-10 years out; rising rates increase discount rates and compress NPV of future drug sales. The 10-year Treasury yield directly impacts biotech sector multiples - the 2022 rate spike crushed biotech indices 40-60%. Additionally, higher rates increase opportunity cost of holding cash-burning equities versus risk-free alternatives. Operationally, interest income on cash balances provides minor offset (~5% on $170M = $8.5M annually at current rates).
Minimal - Company maintains minimal debt (0.02 D/E ratio) and funds operations through equity. No exposure to credit market disruptions for operational financing. However, broader biotech M&A and partnership activity slows during credit contractions, potentially delaying monetization opportunities.
growth/momentum - Pure speculation on binary clinical outcomes attracts high-risk tolerance investors seeking 3-10x returns on successful drug approval. The 171% six-month surge indicates strong momentum trader presence. Institutional ownership likely concentrated in specialized healthcare/biotech funds (Perceptive Advisors, RTW Investments, RA Capital) rather than broad index funds. Minimal dividend/value investor interest given zero cash generation and negative ROE/ROA.
high - Clinical-stage biotech volatility typically 2-3x market (beta >2.0). Single-day moves of 20-40% common around data releases. The 83% three-month return demonstrates extreme price sensitivity to sentiment shifts. Options market likely prices elevated implied volatility (60-100%+) around known catalyst dates.
